Stock Analysis
- Brazil
- /
- Healthcare Services
- /
- BOVESPA:FLRY3
Analysts Have Been Trimming Their Fleury S.A. (BVMF:FLRY3) Price Target After Its Latest Report
Shareholders might have noticed that Fleury S.A. (BVMF:FLRY3) filed its yearly result this time last week. The early response was not positive, with shares down 5.5% to R$11.09 in the past week. It was an okay result overall, with revenues coming in at R$7.7b, roughly what the analysts had been expecting. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
See our latest analysis for Fleury
Following the latest results, Fleury's nine analysts are now forecasting revenues of R$8.27b in 2025. This would be a reasonable 7.6% improvement in revenue compared to the last 12 months. Before this earnings report, the analysts had been forecasting revenues of R$8.24b and earnings per share (EPS) of R$1.28 in 2025. So we can see that while the consensus made no real change to its revenue estimates, it also no longer provides an earnings per share estimate. This suggests that revenues are what the market is focusing on after the latest results.
The average price target fell 6.7% to R$15.25, withthe analysts clearly having become less optimistic about Fleury'sprospects following its latest earnings. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Fleury at R$19.50 per share, while the most bearish prices it at R$11.50. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Fleury's past performance and to peers in the same industry. It's pretty clear that there is an expectation that Fleury's revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 7.6% growth on an annualised basis. This is compared to a historical growth rate of 23% over the past five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 9.7% annually. Factoring in the forecast slowdown in growth, it seems obvious that Fleury is also expected to grow slower than other industry participants.
The Bottom Line
The most important thing to take away is that the analysts reconfirmed their revenue estimates for next year, suggesting that the business is performing in line with expectations. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Fleury's revenue is expected to perform worse than the wider industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.
At least one of Fleury's nine analysts has provided estimates out to 2027, which can be seen for free on our platform here.
We don't want to rain on the parade too much, but we did also find 1 warning sign for Fleury that you need to be mindful of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BOVESPA:FLRY3
Fleury
Provides medical services in the diagnostic, treatment, clinical analysis, health management, medical care, orthopedics, and ophthalmology areas in Brazil.